MCK MCKESSON CORP
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 927653 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY16.5%
TTM EPS YoY21.1%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR10.5%
Margins
Gross margin3.7%
Operating margin1.6%
Net margin1.1%
FCF margin1.7%
EBITDA margin1.7%
Returns
ROE—
ROA5.3%
ROIC (approx.)1,481.2%
Asset turnover4.75x
Leverage & solvency
Liabilities / assets101.1%
Debt / equity—
Current ratio0.90x
Interest coverage21.87x
Cash quality & payout
Operating cash flow / net income1.60x
Accruals ratio-3.2%
Payout ratio8.5%
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $110.96B | $105.38B | $96.30B | $106.16B | $103.15B | $97.83B | $90.82B | $95.29B |
| Cost of revenue | $107.00B | $101.69B | $92.25B | $102.47B | $99.61B | $94.55B | $87.18B | $92.01B |
| Gross profit | $3.96B | $3.69B | $4.04B | $3.69B | $3.54B | $3.28B | $3.64B | $3.28B |
| SG&A expense | $2.27B | $2.26B | $1.80B | $2.03B | $2.07B | $2.20B | $1.98B | $2.03B |
| Operating income | $1.60B | $1.32B | $2.15B | $1.62B | $1.41B | $1.04B | $1.59B | $1.22B |
| Interest expense | $105.00M | $77.00M | $61.00M | $63.00M | $74.00M | $49.00M | $45.00M | $67.00M |
| Pretax income | $1.56B | $1.31B | $2.12B | $1.63B | $1.40B | $1.05B | $1.51B | $1.23B |
| Income tax | $266.00M | $276.00M | $270.00M | $380.00M | $232.00M | $220.00M | $209.00M | $298.00M |
| Net income | $1.22B | $614.00M | $1.68B | $1.19B | $1.11B | $784.00M | $1.26B | $879.00M |
| EBITDA | $1.80B | $1.51B | $1.90B | $1.81B | $1.59B | $1.19B | $1.38B | $1.38B |
| EPS (basic) | 10.47 | 5.17 | — | 9.63 | 8.95 | 6.28 | — | 6.98 |
| EPS (diluted) | 10.44 | 5.15 | — | 9.59 | 8.92 | 6.25 | — | 6.95 |
| Dividends declared per share | 0.94 | 0.82 | 0.82 | 0.82 | 0.82 | 0.71 | 0.71 | 0.71 |
| Weighted avg. shares (diluted) | 116.70M | 119.20M | — | 123.70M | 124.40M | 125.50M | — | 126.60M |
| Balance sheet | ||||||||
| Cash & equivalents | $6.53B | $5.16B | $3.98B | $2.96B | $4.00B | $2.42B | $5.96B | $1.13B |
| Receivables | $30.81B | $30.32B | $27.98B | $28.21B | $28.29B | $28.16B | $25.64B | $25.83B |
| Inventory | $28.22B | $26.26B | $24.21B | $27.07B | $26.13B | $25.07B | $23.00B | $23.84B |
| Current assets | $66.69B | $62.84B | $57.21B | $59.70B | $59.89B | $56.80B | $55.40B | $51.74B |
| PP&E, net | $2.67B | $2.68B | $2.67B | $2.63B | $2.63B | $2.57B | $2.50B | $2.40B |
| Goodwill | $11.27B | $11.28B | $11.32B | $11.32B | $11.28B | $11.37B | $10.02B | $10.00B |
| Intangibles | $3.94B | $4.01B | $4.08B | $4.18B | $4.22B | $4.27B | $1.46B | $1.51B |
| Total assets | $92.32B | $88.33B | $82.32B | $84.19B | $84.16B | $81.31B | $75.14B | $71.08B |
| Current liabilities | $74.40B | $70.36B | $67.02B | $68.13B | $68.03B | $64.33B | $61.60B | $58.56B |
| Short-term debt | $794.00M | $1.30B | $1.27B | $1.13B | $1.75B | $1.25B | $1.19B | $2.42B |
| Long-term debt | $8.41B | $8.43B | $5.26B | $5.42B | $6.01B | $6.53B | $4.46B | $4.42B |
| Total debt | $9.21B | $9.73B | $6.53B | $6.56B | $7.76B | $7.78B | $5.65B | $6.85B |
| Total liabilities | $93.34B | $89.63B | $83.16B | $84.29B | $84.74B | $82.17B | $76.83B | $73.78B |
| Shareholders' equity | -$3.95B | -$4.24B | -$2.17B | -$1.30B | -$1.74B | -$1.97B | -$2.07B | -$3.08B |
| Net debt | $2.68B | $4.57B | $2.55B | $3.60B | $3.75B | $5.36B | -$302.00M | $5.72B |
| Cash flow statement | ||||||||
| Operating cash flow | $3.07B | -$220.00M | $3.42B | $1.23B | $2.42B | -$918.00M | $7.75B | -$2.38B |
| Capital expenditure | $65.00M | $112.00M | $111.00M | $108.00M | $106.00M | $111.00M | $169.00M | $126.00M |
| Free cash flow | $3.00B | -$332.00M | $3.31B | $1.12B | $2.31B | -$1.03B | $7.58B | -$2.51B |
| Investing cash flow | -$130.00M | -$214.00M | $425.00M | -$269.00M | -$24.00M | -$3.56B | -$224.00M | -$136.00M |
| Financing cash flow | -$1.57B | $1.63B | -$2.82B | -$2.03B | -$961.00M | $1.18B | -$2.85B | $1.30B |
| Depreciation & amortization | $197.00M | $195.00M | -$246.00M | $188.00M | $188.00M | $157.00M | -$213.00M | $153.00M |
| Dividends paid | $96.00M | $102.00M | $101.00M | $101.00M | $89.00M | $90.00M | $91.00M | $92.00M |
| Share buybacks | $894.00M | $2.53B | $2.67B | $680.00M | $818.00M | $581.00M | $300.00M | $827.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.